300347 Hangzhou Tigermed Consulting Co.,Ltd.
Closed 12-26 15:00:00
55.11
+0.26
+0.47%
High55.49Low54.15Vol8.85M
Open55.22D1 Closing54.85Amplitude2.44%
Mkt Cap47.45BTradable Cap31.19BTotal Shares861.00M
T/O486.00MT/O Rate1.56%Tradable Shares566.00M
P/B2.23ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Delisted from Shenzhen 100, Market Cap Evaporates by 100 Billion: How Can Tigermed Overcome Its "Investment Dependence"?
Deep News  ·  12-25 17:41
Delisted from Shenzhen 100, Market Cap Evaporates by 100 Billion: How Can Tigermed Overcome Its "Investment Dependence"?
TIGERMED Removed from SZSE 100 Index After Losing Over 100 Billion in Market Value
Deep News  ·  12-18
TIGERMED Removed from SZSE 100 Index After Losing Over 100 Billion in Market Value
Frontage Holdings Corporation Announces Date for Extraordinary General Meeting
Reuters  ·  12-12
Frontage Holdings Corporation Announces Date for Extraordinary General Meeting
Frontage Holdings Corporation to Vote on Share Transfer Agreement and Acquisition at Upcoming Shareholder Meeting
Reuters  ·  12-12
Frontage Holdings Corporation to Vote on Share Transfer Agreement and Acquisition at Upcoming Shareholder Meeting
Xingquan Global Fund Reduces Stake in TIGERMED (03347) by 216,800 Shares at HK$37.7 per Share
Stock News  ·  12-04
Xingquan Global Fund Reduces Stake in TIGERMED (03347) by 216,800 Shares at HK$37.7 per Share
JPMorgan Reduces Stake in TIGERMED (03347) by Approximately 831,200 Shares at Average Price of HK$39.82 per Share
Stock News  ·  12-01
JPMorgan Reduces Stake in TIGERMED (03347) by Approximately 831,200 Shares at Average Price of HK$39.82 per Share
JPMorgan Increases Stake in Tigermed (03347) by Approximately 501,500 Shares at HK$38.95 per Share
Stock News  ·  11-27
JPMorgan Increases Stake in Tigermed (03347) by Approximately 501,500 Shares at HK$38.95 per Share
TIGERMED (03347) Rises Over 4% as Q3 Revenue Shows Significant Improvement with Double-Digit Growth in SMO New Orders
Stock News  ·  11-10
TIGERMED (03347) Rises Over 4% as Q3 Revenue Shows Significant Improvement with Double-Digit Growth in SMO New Orders
CLSA Maintains Outperform Rating on TIGERMED (03347) Amid Q3 Moderate Recovery
Stock News  ·  10-30
CLSA Maintains Outperform Rating on TIGERMED (03347) Amid Q3 Moderate Recovery
TIGERMED (03347) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.45% YoY to RMB1.02 Billion
Stock News  ·  10-28
TIGERMED (03347) Reports Q3 Results: Net Profit Attributable to Shareholders Rises 25.45% YoY to RMB1.02 Billion
E Fund Reduces Stake in TIGERMED (03347) by 429,800 Shares at Approximately HKD 42.78 per Share
Stock News  ·  10-24
E Fund Reduces Stake in TIGERMED (03347) by 429,800 Shares at Approximately HKD 42.78 per Share
EFUND Investment Management Increases Stake in TIGERMED (03347) by 573,100 Shares at Approximately HK$42.09 Each
Stock News  ·  10-16
EFUND Investment Management Increases Stake in TIGERMED (03347) by 573,100 Shares at Approximately HK$42.09 Each
Goldman Sachs Initiates Coverage on TIGERMED (03347) H-Shares with "Buy" Rating, HK$62.1 Target Price
Stock News  ·  10-14
Goldman Sachs Initiates Coverage on TIGERMED (03347) H-Shares with "Buy" Rating, HK$62.1 Target Price
Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics
Reuters  ·  09-29
Onco-Innovations Launches Preclinical Development of PNKP Inhibitor with Validated Analytical Methods by Nucro-Technics
TIGERMED Rises Over 5% in Early Trading as Overseas Clinical Operations Show Strong Growth
Deep News  ·  09-24
TIGERMED Rises Over 5% in Early Trading as Overseas Clinical Operations Show Strong Growth
E Fund Management Reduces TIGERMED (03347) Holdings by 876,900 Shares at Approximately HK$46.57 Per Share
Stock News  ·  09-22
E Fund Management Reduces TIGERMED (03347) Holdings by 876,900 Shares at Approximately HK$46.57 Per Share
E Fund Management Reduces Stake in TIGERMED (03347) by 4.17 Million Shares at HK$44.34 Per Share
Stock News  ·  09-16
E Fund Management Reduces Stake in TIGERMED (03347) by 4.17 Million Shares at HK$44.34 Per Share
TIGERMED to Hold First Extraordinary General Meeting of 2025 on September 29
Deep News  ·  09-08
TIGERMED to Hold First Extraordinary General Meeting of 2025 on September 29
JPMorgan Increases Holdings in TIGERMED (03347) by 343,700 Shares at Approximately HK$46.98 Per Share
Stock News  ·  09-04
JPMorgan Increases Holdings in TIGERMED (03347) by 343,700 Shares at Approximately HK$46.98 Per Share
BOC International Raises TIGERMED (03347) Target Price to HK$51, Maintains "BUY" Rating
Stock News  ·  09-03
BOC International Raises TIGERMED (03347) Target Price to HK$51, Maintains "BUY" Rating

Introduction

Company Name.
杭州泰格医药科技股份有限公司
Industry:
研究和试验发展
Listing Date:
2012-08-17
Main Business:
　　杭州泰格医药科技股份有限公司的主营业务是为新药研发提供临床试验全过程专业服务的合同研究组织（CRO），为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。公司的主要产品是临床运营、临床药理、注册与法规事务、科学事务、医学翻译、药物警戒、真实世界研究、第三方稽查与培训、数据管理及统计分析、临床试验现场管理、受试者招募、医学影像以及实验室。
Issue price:
37.88